The estimated Net Worth of Thomas Wilder is at least $1.06 millió dollars as of 7 August 2023. Mr. Wilder owns over 340 units of Penumbra Inc stock worth over $68,785 and over the last 15 years he sold PEN stock worth over $815,576. In addition, he makes $179,968 as Independent Director at Penumbra Inc.
Thomas has made over 31 trades of the Penumbra Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 340 units of PEN stock worth $86,183 on 7 August 2023.
The largest trade he's ever made was selling 27,864 units of Penumbra Inc stock on 12 August 2020 worth over $2,229. On average, Thomas trades about 1,823 units every 78 days since 2010. As of 7 August 2023 he still owns at least 340 units of Penumbra Inc stock.
You can see the complete history of Mr. Wilder stock trades at the bottom of the page.
Thomas (Tom) C. Wilder III serves as Independent Director of the Company. Mr. Wilder has served as the Chief Executive Officer of Neuros Medical, Inc., a neuro-modulation company. From February 2010 through July 2016, Mr. Wilder served as the Chief Executive Officer of Sequent Medical, Inc., a company dedicated to the development of innovative catheter-based neurovascular technologies. From April 2006 to 2009, Mr. Wilder served as the President and CEO of PhotoThera, Inc., a company that was developing a unique therapy for acute ischemic stroke patients. From 2002 to 2006, he served as the President and CEO of MicroTherapeutics, Inc. (MTIX), a company also focused on the neurovascular space. Mr. Wilder served in positions of increasing responsibility at Medtronic, Inc. from 1991 through 2002, most recently as Vice President and General Manager of its endovascular stent grafts division. Mr. Wilder began his career in the Financial Statement Audit Practice of Price Waterhouse, where he worked from 1986 to 1989. He received a B.A. from Stanford University and an M.B.A. from Northwestern University’s Kellogg Graduate School of Management and currently serves on the Board of Directors of Endologix, Inc. (ELGX).
As the Independent Director of Penumbra Inc, the total compensation of Thomas Wilder at Penumbra Inc is $179,968. There are 14 executives at Penumbra Inc getting paid more, with Johanna Roberts having the highest compensation of $2,556,370.
Thomas Wilder is 56, he's been the Independent Director of Penumbra Inc since 2017. There are 7 older and 9 younger executives at Penumbra Inc. The oldest executive at Penumbra Inc is Don Kassing, 78, who is the Presiding Independent Director.
Thomas's mailing address filed with the SEC is 2, Musick, Irvine Spectrum, Irvine, Orange, California, 92618, United States of America.
Over the last 9 years, insiders at Penumbra Inc have traded over $197,637,326 worth of Penumbra Inc stock and bought 700 units worth $109,480 . The most active insiders traders include Adam Elsesser, Arani Bose és James Robert Pray. On average, Penumbra Inc executives and independent directors trade stock every 9 days with the average trade being worth of $2,030,383. The most recent stock trade was executed by Harpreet Grewal on 4 September 2024, trading 782 units of PEN stock currently worth $159,614.
penumbra is a specialty interventional therapies company that develops and markets innovative medical devices to treat challenging medical conditions with significant unmet clinical needs. we design our therapies to provide our specialist physician customers with improved clinical outcomes through faster and safer procedures at significant overall cost savings to the healthcare system. today we have over 1,000 employees with sales operations in north america, europe, australia and asia.
Penumbra Inc executives and other stock owners filed with the SEC include: